Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Wyeth Pharmaceuticals and Ablynx have agreed to discover, develop, and commercialize Ablynx's therapeutic proteins, trade-named Nanobodies, which are directed at the tumor necrosis factor alpha protein and its receptors. Ablynx will receive an initial payment, research support, and milestone payments that could total $212.5 million. In addition, Ablynx will receive royalties on product sales.
This article has been sent to the following recipient: